What Cell One Partners does

Cell One Partners Inc. is a privately held strategic consulting firm founded in 2018 by George S. Goldberger, operating since 2019, and headquartered in New York, USA. The firm provides advisory services exclusively to the cell and gene therapy (CGT) industry, supporting clients across clinical development, manufacturing strategy, regulatory pathway development, commercialization infrastructure, human capital, and contract management. Its service portfolio includes six core offerings: Clinical Development Consulting, Market and Science Assessment, Process Development & Manufacturing, Commercialization Infrastructure, Human Capital Management, and Contract Management Services. Delivery is structured around a 4-person leadership team, a core team of 28+ experts, and a network of strategic advisors sourced from senior operating roles at Novartis, GSK, Amgen, Roche, Lonza, and Kite Pharma, as well as former CDMO executives from PCT/Minaris and PharmaCell.

The business model is professional services consulting with tailored, project-based engagements; no public pricing is disclosed. Customer segments span CGT developers (startups and emerging companies), CGT service providers including CDMOs and viral vector manufacturers, and private equity firms seeking market diligence for acquisitions and roll-up strategies. Disclosed engagements include $500M and $1B-scale PE due diligence projects, FDA Complete Response Letter responses, GMP audits, and market analyses spanning CGT, CDMO, viral vector, and tools markets. The firm is founder-owned, with no institutional investors or parent company identified, and operates a distributed delivery model across North America, Europe, the Middle East, and Asia Pacific. In November 2025, Cell One Partners extended beyond pure advisory through a partnership with Conner Strong & Buckelew and Citadel Insurance to co-develop the Product Shortage PLUS Endorsement, a specialized insurance product addressing CGT supply-chain risk.

Name

Cell One Partners

Legal name

Cell One Partners Inc.

Website

https://cellonepartners.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Cell One Partners is a New York-based strategic consulting firm founded in 2018 that advises cell and gene therapy developers, CDMOs, and private equity firms on clinical, manufacturing, regulatory, and commercialization strategy via a 30+ expert bench.

Ownership category

akta.pro rank

Product category

Biotechnology Consulting

NAICS

Management Consulting Services (54161)

SIC

Services-Management Consulting Services (8742)

akta.pro primary industry

Cell Therapy CDMO (HLAGABAD)

akta.pro secondary industry

Cell Therapy Clinical Services & Treatment Centers (apheresis, administration, monitoring) (HLAAABAJ)

Keywords

• Cell therapy consulting
• Gene therapy advisory
• Commercialization strategy
• Biotech regulatory consulting
• CDMO due diligence

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

1. Strategic Consulting Services: Professional consulting services provided to cell and gene therapy companies, including clinical development planning, manufacturing strategy, regulatory pathway development, market assessment, and due diligence support. Services are tailored to client needs through flexible engagement structures.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Cell One Partners is a strategic consulting firm that helps cell and gene therapy (CGT) companies advance from laboratory to clinic to commercialization through tailored advisory engagements. Its offerings span clinical development planning, market and pipeline assessment, process development and manufacturing strategy, commercialization infrastructure setup, human capital management, and contract management services for emerging clients. Each engagement is staffed by an experienced client team drawn from a network of more than 30 industry experts and former executives from major pharmaceutical, biotech, and CDMO organizations.

Product overview

Cell One Partners is a strategic consulting firm for cell and gene therapy companies, not a software product company. The company offers a portfolio of consulting services organized around the commercialization pathway for advanced therapy medicinal products (ATMPs). Their service offerings include: Clinical Development Consulting (clinical plan development, assessment reports, bioprocessing, analytical development, closed and automated processing, cost of goods analysis), Market and Science Assessment (pipeline asset evaluation, in-licensing options), Process Development & Manufacturing (manufacturing platform development, CMO management, technology transfers, GMP manufacturing), Commercialization Infrastructure (supply chain development, facility setup, IT infrastructure, regulatory submission, market access), and Human Capital Management (HR strategies, talent acquisition, organizational development). The company also provides access to a network of strategic advisors and industry insiders. There is no unified software platform; rather, Cell One Partners delivers hands-on expert consulting engagements tailored to client needs throughout the development and commercialization continuum.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Development Consulting Strategic consulting support for cell and gene therapy companies covering clinical plan development, assessment reports, bioprocessing, analytical development, closed and automated processing, and cost of goods analysis. Targeted at CGT development companies needing expert guidance on clinical development strategy.
• Market and Science Assessment Evaluation services for in-licensing of pipeline assets and market opportunity assessment within the cell and gene therapy industry. Designed for CGT companies and investors seeking expert market and pipeline analysis.
• Process Development & Manufacturing Manufacturing strategy services for cell and gene therapy companies, including robust manufacturing platform development, CMO selection, contract negotiation, ongoing management, process development, technology transfers, and GMP manufacturing support. Targeted at CGT developers and CDMOs.
• Commercialization Infrastructure Development and establishment of commercialization infrastructure for cell and gene therapy products, including supply chain development, facility setup and FDA inspection, IT infrastructure, logistics, regulatory submission, and market access approach including billing code strategies and pricing and reimbursement strategy. Intended for CGT developers advancing toward commercial launch.
• Human Capital Management Implementation of human capital strategies for cell and gene therapy organizations, including HR due diligence with leadership team assessment, talent acquisition, organizational design and development, compensation and benefits plan design, and creation of a best-in-class culture. Targeted at CGT companies and investors requiring HR due diligence and organizational development support.
• Contract Management Services Comprehensive contract management services for emerging cell and gene therapy clients, supporting the negotiation, administration, and ongoing management of contracts associated with clinical development, manufacturing, and commercialization. Targeted at emerging CGT companies that need expert contract support alongside broader commercialization engagements.

Quantifiable outcome

• Supported client in achieving FDA IND approval for gene therapy product within mandated timelines
• +1 more outcomes

Named customers8 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Three partnerships are on record, tiered core and minor.

• Conner Strong & BuckelewcoreStrategic or Co-development Partner · 3 November 2025Cell One Partners collaborated with Conner Strong & Buckelew to develop the Product Shortage PLUS Endorsement insurance solution for cell and gene therapy product shortages. This coverage addresses risks related to patient claims, operational failures, legal defense, and compliance in clinical trials, helping companies mitigate risks associated with complex supply chain and treatment delivery.
• Citadel Insurance (BioPro program)coreStrategic or Co-development Partner · 3 November 2025The Product Shortage PLUS Endorsement is offered through Citadel Insurance's BioPro program, developed in collaboration with Cell One Partners to address risks in the cell and gene therapy industry.
• AES (Advanced Equipment Services)minorStrategic or Co-development PartnerCell One Partners partners with AES for designing cleanroom facilities for cell and gene therapy companies.

Scale indicators3 records

Recent moves5 records

Expansion highlights6 records

Direct peers

• Trinity Partners: Strategic consulting firm dedicated to life sciences, advising biopharmaceutical clients on strategy, pricing, and commercialization — directly comparable to Cell One Partners' biotech strategy and commercialization advisory offering.
• Health Advances: Strategy consulting firm focused exclusively on healthcare and biotechnology, providing commercial, pipeline, and market access strategy to biopharma and medtech clients across all therapeutic areas, including advanced therapies.
• Putnam Associates: Biopharmaceutical strategy consulting firm advising global pharma and biotech on commercial strategy, pricing, and market access — directly comparable in business model and target client base.
• Lumanity: Biotech and pharma consulting firm (formerly including Defined Health and other life-sciences consultancies) providing strategic advisory, HEOR, and medical communications to biopharma, with overlap in advanced therapy strategy.
• Back Bay Life Science Advisors: Life sciences-focused advisory firm providing strategic counsel and capital markets advisory to medtech, biotech, and digital health companies — comparable boutique peer in life-sciences strategy advisory.

Broad incumbents

• IQVIA (Consulting & Analytics): Large global life-sciences services and consulting firm serving pharma, biotech, and medtech across R&D, clinical, and commercial; competes for high-end biopharma strategy mandates with much broader portfolio.
• Syneos Health Consulting: Biopharmaceutical services organization with a dedicated consulting practice covering R&D, medical, and commercial strategy for pharma/biotech — broader incumbent overlapping in CGT commercialization advisory.
• Charles River Associates: Global management consulting firm with a Life Sciences practice providing strategy, litigation, and economic advisory to biopharmaceutical clients; broader incumbent with adjacent offerings.
• Bain & Company (Life Sciences practice): Top-tier global strategy consultancy with a dedicated Life Sciences practice advising biopharma on corporate strategy, commercial, and operations — broader incumbent at the high end of strategic advisory.
• McKinsey & Company (Biopharma practice): Global management consultancy with a large Biopharma practice covering R&D, manufacturing, and commercial strategy for pharma and biotech, including advanced therapies — broadest-scale incumbent.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cell One Partners